Compare NP & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | DNLI |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | N/A | 2017 |
| Metric | NP | DNLI |
|---|---|---|
| Price | $24.47 | $19.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $27.04 | ★ $34.09 |
| AVG Volume (30 Days) | 325.5K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.45 | N/A |
| Revenue Next Year | $15.74 | $188.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $10.57 |
| 52 Week High | $31.75 | $23.77 |
| Indicator | NP | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 47.30 |
| Support Level | $24.29 | $18.56 |
| Resistance Level | $26.85 | $20.12 |
| Average True Range (ATR) | 1.42 | 1.14 |
| MACD | 0.37 | -0.21 |
| Stochastic Oscillator | 91.47 | 30.89 |
Neptune Insurance Holdings Inc is a high-growth, data-driven MGA that is revolutionizing the way homeowners and businesses protect against the growing risks of flooding. It offers a range of easy-to-purchase residential and commercial insurance products - including primary flood insurance, excess flood insurance, and parametric earthquake insurance - distributed through a nationwide network of agencies. It underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies, whom the company refer to as capacity providers, that manage both this risk and the associated claims handling.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.